Polina Sysa-Shah
Overview
Explore the profile of Polina Sysa-Shah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Yang X, Minn I, Rowe S, Banerjee S, Gorin M, Brummet M, et al.
Oncotarget
. 2015 Sep;
6(32):33733-42.
PMID: 26418876
We developed a new scaffold for radionuclide-based imaging and therapy of clear cell renal cell carcinoma (ccRCC) targeting carbonic anhydrase IX (CAIX). Compound XYIMSR-01, a DOTA-conjugated, bivalent, low-molecular-weight ligand, has...
22.
Sysa-Shah P, Sorensen L, Abraham M, Gabrielson K
Comp Med
. 2015 Aug;
65(4):295-307.
PMID: 26310459
Electrocardiography is an important method for evaluation and risk stratification of patients with cardiac hypertrophy. We hypothesized that the recently developed transgenic mouse model of cardiac hypertrophy (ErbB2(tg)) will display...
23.
Belmonte F, Das S, Sysa-Shah P, Sivakumaran V, Stanley B, Guo X, et al.
Am J Physiol Heart Circ Physiol
. 2015 Aug;
309(8):H1271-80.
PMID: 26254336
Levels of the HER2/ErbB2 protein in the heart are upregulated in some women during breast cancer therapy, and these women are at high risk for developing heart dysfunction after sequential...
24.
Kageyama Y, Hoshijima M, Seo K, Bedja D, Sysa-Shah P, Andrabi S, et al.
EMBO J
. 2014 Oct;
33(23):2798-813.
PMID: 25349190
Mitochondrial dynamics and mitophagy have been linked to cardiovascular and neurodegenerative diseases. Here, we demonstrate that the mitochondrial division dynamin Drp1 and the Parkinson's disease-associated E3 ubiquitin ligase parkin synergistically...
25.
Sysa-Shah P, Xu Y, Guo X, Pin S, Bedja D, Bartock R, et al.
Mol Cancer Ther
. 2014 Apr;
13(7):1717-28.
PMID: 24737026
Doxorubicin is a widely used chemotherapy for solid tumors and hematologic malignancies, but its use is limited due to cardiotoxicity. Geranylgeranylacetone (GGA), an antiulcer agent used in Japan for 30...
26.
Auer D, Sysa-Shah P, Bedja D, Simmers J, Pak E, Dutra A, et al.
Biotechnol Lett
. 2014 Feb;
36(6):1179-85.
PMID: 24563304
Polymorphic non-coding variants at the NOS1AP locus have been associated with the common cardiac, metabolic and neurological traits and diseases. Although, in vitro gene targeting-based cellular and biochemical studies have...
27.
Yap K, Sysa-Shah P, Bolon B, Wu R, Gao M, Herlinger A, et al.
PLoS One
. 2013 Aug;
8(7):e69099.
PMID: 23922682
NAC1 encoded by NACC1 is a member of the BTB/POZ family of proteins and participates in several pathobiological processes. However, its function during tissue development has not been elucidated. In...
28.
Sysa-Shah P, Xu Y, Guo X, Belmonte F, Kang B, Bedja D, et al.
PLoS One
. 2012 Aug;
7(8):e42805.
PMID: 22912742
Background: Emerging evidence shows that ErbB2 signaling has a critical role in cardiomyocyte physiology, based mainly on findings that blocking ErbB2 for cancer therapy is toxic to cardiac cells. However,...
29.
Pramanik D, Campbell N, Das S, Gupta S, Chenna V, Bisht S, et al.
Oncotarget
. 2012 Jul;
3(6):640-50.
PMID: 22791660
Acquired chemotherapy resistance is a major contributor to treatment failure in oncology. For example, the efficacy of the common anticancer agent doxorubicin (DOX) is limited by the emergence of multidrug...